IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 4. (Canceled)

5. (Currently Amended) An isolated polypeptide selected from the group consisting of:

a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:3; and

b) ~~a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 300 contiguous amino acids of SEQ ID NO:2 and wherein said at least 300 contiguous amino acids have kinase activity;~~

~~c) an antigenic fragment of SEQ ID NO:2 comprising at least 15 amino acid residues of SEQ ID NO:2; and~~

~~d)~~ a polypeptide ~~having the~~ comprising amino acid ~~sequence~~ residues 1 to 350 of SEQ ID NO:2, wherein the polypeptide has kinase activity.

6. (Previously Presented) The polypeptide of claim 5 further comprising heterologous amino acid sequences.

7. – 11. (Canceled)

12. (Withdrawn) A method for identifying a compound which binds to a polypeptide of claim 5 comprising the steps of:

a) contacting a polypeptide, or a cell expressing a polypeptide of claim 5 with a test compound; and

b) determining whether the polypeptide binds to the test compound.

13. (Currently Amended) The method of claim 12, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) detection of binding by direct detecting of test compound/polypeptide binding;

b) detection of binding using a competition binding assay; ~~and~~

c) detection of binding using an assay for protein kinase-mediated phosphorylation; and

d) detection of binding using a two-hybrid assay.

14. (Canceled)

15. (Withdrawn) A method for identifying a compound which modulates the activity of a polypeptide of claim 5, comprising:

a) contacting a polypeptide of claim 5 with a test compound; and

b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound that modulates the activity of the polypeptide.

16. (Withdrawn) The method of claim 15, wherein the activity of the polypeptide is determined in a kinase assay using a 14171 kinase substrate.

17. – 20. (Canceled)

21. (New) The polypeptide of claim 5, wherein the polypeptide comprises SEQ ID NO:2.

22. (New) The polypeptide of claim 6, wherein the heterologous amino acid sequences are selected from the group consisting of glutathione-S-transferase, V5 and histidine residues.

23. (New) The method of claim 12, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

24. (New) The method of claim 12, wherein the polypeptide is immobilized on a solid surface.

25. (New) The method of claim 12, wherein the test compound is directly or indirectly labeled.

26. (New) The method of claim 15, wherein the activity of the polypeptide is the ability to bind ATP.

27. (New) The method of claim 15, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

28. (New) The method of claim 16, wherein the 14171 kinase substrate has a T-P motif.

29. (New) The method of claim 15, wherein the polypeptide is expressed in a cell and the test compound is contacted with the cell expressing the polypeptide.

30. (New) The method of claim 29, wherein the activity of the polypeptide is selected from the group consisting of:

a) phosphorylation activity; and

b) apoptosis.

31. (New) The method of claim 29, wherein the cell is selected from a group consisting of an epithelial cell and a tumor cell.

32. (New) The method of claim 29, wherein the activity of the polypeptide is determined by determining the activity of a target molecule.

33. (New) The method of claim 32, wherein the activity of the target molecule is selected from the group consisting of:

a) cellular second messenger activity,

b) catalytic/enzymatic activity,

c) reporter gene induction, and

d) cellular growth, differentiation or proliferation.

34. (New) The method of claim 33, wherein the reporter gene induction follows activity selected from the group consisting of nuclear factor-kappaB activity and interleukin-8 activity.